|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Tinea Capitis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Tinea | |||||
| 3 | More general conditions related to this trial | ||||
| Dermatomycoses | |||||
| Infection | |||||
| Mycoses | |||||
| Scalp Dermatoses | |||||
| Skin Diseases | |||||
| Skin Diseases, Infectious | |||||
| 4 | Interventions listed in this trial | ||||
| Terbinafine hydrochloride (HCl) | |||||
| Griseofulvin | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Terbinafine | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Antibiotics, Antifungal | |||||
| Antifungal Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Novartis | |||||